

Lao PDR Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Lao PDR					
2. Grant number: 1720-LAO-18e-X / 17-LAO-08k-Y					
3. Date of Decision Letter: 4 December 2017					
4. Date of the Partnership Framework Agreement: 7 June 2013					
5. Programme title: New Vaccine Support (NVS), Measles-Rubella first and second dose routine (two dose schedule) Routine					
6. Vaccine type: Measles-Rubella					
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED					
8. Programme duration¹: 2017 - 2020					
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)					
	2017	2018	2019	2020	Total ²
Programme Budget (US\$)	77,000	161,500	110,500	72,500	421,500
10. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³					

Type of supplies to be purchased with Gavi funds in each year (Routine)		2017	2018		
Number of Measles-Rubella vaccines doses		122,200	251,900		
Annual Amounts (US\$)		77,000	161,500		

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

11. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

12. Self-procurement: N/A

13. Co-financing obligations for routine: Reference code: 1720-LAO-18e-X-C
According to the co-financing policy, the Country falls within the group Accelerated Transition.
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017	2018	2019	2020
Number of vaccine doses	99,100	319,600	364,500	441,100
Number of AD syringes	74,000	230,000		
Number of re-constitution syringes	10,900	35,200		
Number of safety boxes	950	2,925		
Value of vaccine doses (US\$)	60,418	197,455		
Total co-financing payments (US\$) (including freight)	66,500	217,000	246,500	298,500
Minimum number of doses to be financed from domestic resources	50,790	143,758	127,384	127,719
Minimum amount to be financed from domestic resources (US\$)	30,982	88,842	78,724	78,931

14. Co-financing obligations for campaign: N/A

15. Vaccine introduction grant (in US\$): A VIG of US\$149,330 was disbursed 1 August 2017

16. Operational support for campaigns: Not applicable

17. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

18. Financial clarifications: N/A

19. Other conditions: As a condition to Gavi's support for measles and rubella, Country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
21 December 2017